BOSTON - Cohere Health, a company specializing in clinical intelligence and prior authorization automation, has announced the expansion of its partnership with Humana Inc . (NYSE: NYSE:HUM), a leading health and well-being company. Humana will increase the use of Cohere's prior authorization platform to include diagnostic imaging and sleep services.
The collaboration aims to improve the efficiency of prior authorizations, a common administrative process in healthcare that can often delay patient care. By leveraging Cohere's technology, Humana seeks to streamline these tasks for providers and enhance the healthcare journey for its members.
In January 2021, Humana initiated a pilot program with Cohere in 12 states focused on musculoskeletal (MSK) services. The program's success in reducing approval times and enhancing provider satisfaction led to its expansion to all 50 states the following year. In January 2023, Cohere's solutions were also applied to cardiovascular and surgical services nationwide.
Cohere's platform is designed to support faster diagnosis and treatment by aligning patient services with care pathways based on the latest evidence-based guidelines. The technology also aims to reduce the rate of prior authorization denials, thus providing quicker access to necessary care for patients.
This expansion is expected to have a significant impact, as Cohere processes over 5.5 million prior authorizations annually. This affects more than 15 million health plan members and 420,000 healthcare providers across the United States.
Cohere Health has been recognized for its innovative solutions, including being named a Top 5 LinkedIn™ Startup and a recipient of the TripleTree iAward. It has also been featured on Fierce Healthcare's Fierce 15 and CB Insights' Digital Health 150 lists.
Humana serves a diverse range of customers, including those with Medicare, Medicaid, military service personnel, and individuals across communities.
The expansion of this partnership between Cohere Health and Humana is based on a press release statement.
InvestingPro Insights
As Humana Inc. (NYSE: HUM) deepens its collaboration with Cohere Health, there are several financial metrics and strategic moves that underline the company's current market position and future potential:
InvestingPro Data indicates that Humana has a robust market capitalization of $39.21 billion, showcasing its significant presence in the healthcare industry. The company's Price/Earnings (P/E) ratio stands at an attractive 13.4, suggesting that the stock may be undervalued relative to its earnings. Additionally, Humana's strong revenue growth of 14.54% in the last twelve months as of Q4 2023 highlights the company's ability to expand its operations successfully.
Among the InvestingPro Tips, it's noteworthy that Humana management has been actively engaged in share buybacks, signaling confidence in the company's value. Moreover, Humana's financial prudence is evident as it holds more cash than debt on its balance sheet, which is a reassuring sign for investors concerned about financial stability.
The company's commitment to shareholder returns is also commendable, with Humana raising its dividend for 7 consecutive years and maintaining dividend payments for 14 consecutive years. This consistent return to shareholders underpins the company's stable financial performance and its role as a prominent player in the Healthcare Providers & Services industry.
For readers interested in a deeper analysis, there are additional InvestingPro Tips available at: https://www.investing.com/pro/HUM. These tips provide further insights into Humana's valuation, cash flow, and profitability. Subscribers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a wealth of expert financial analysis and market data.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.